TECX vs TRVI
TECX: A biotechnology company using its proprietary GEODe™ platform to unlock therapeutic protein and antibody treatments for difficult-to-target GPCR-related diseases. TRVI: Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated with severe lung diseases like IPF.
Side-by-side fundamentals
| Metric | TECX | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $31.59 | $17.36 | |
| Market cap as of 2026-07-23 | $594M | $2.5B | |
| ROE as of 2026-07-23 | -32.3% | -24.5% | TRVI higher |
| ROA as of 2026-07-23 | -30.9% | -23.4% | TRVI higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | TRVI lower |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.30 | 1.02 | |
| 1-year return as of 2026-07-22 close | +49.6% | +166.6% | TRVI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.